Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer
| Autor: | Lisa Licitra, G. Bonadonna, Natalia Pizzi, Pasquale Quattrone, Carlo L. Solero, Giulio Cantù, P. Valagussa, Franco Mattavelli, Laura D. Locati, Luca Gianni, I. Garassino, R. Cavina |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class medicine.medical_treatment Leucovorin Antimetabolite Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine Humans Prospective Studies Infusions Intravenous Prospective cohort study Survival analysis Aged Chemotherapy business.industry Cancer Hematology Middle Aged medicine.disease Survival Analysis Surgery Discontinuation Radiation therapy Treatment Outcome Oncology Female Fluorouracil Cisplatin business Paranasal Sinus Neoplasms |
| Zdroj: | Annals of Oncology. 14:367-372 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdg113 |
| Popis: | To study prospectively the activity of primary chemotherapy with cisplatin, fluorouracil and leucovorin (PFL) in patients with paranasal cancer receiving surgery and postoperative radiotherapy.Forty-nine patients, previously untreated, with resectable paranasal carcinoma were enrolled. PFL (leucovorin 250 mg/m2/day for 5 days as a 120 h continuous infusion (c.i.), 5-fluorouracil 800 mg/m2/day from day 2 as a 96 h c.i. and cisplatin 100 mg/m2 day 2 q 3 weeks) was planned for five courses.Thirty-two patients (65%) completed three or more chemotherapy courses. Two deaths from thrombotic events were observed after the first cycle. Eight cardiac toxicities were recorded during chemotherapy causing treatment discontinuation. Objective response to PFL was observed in 21 patients [43%; 95% confidence interval (CI) 29% to 58%], including four complete responses (CRs) (8%; 95% CI 2% to 20%) and 17 partial responses (PRs) (35%). Pathological complete remission (pCR) was achieved in eight of 49 patients (16%). At 3 years, overall survival was 69% and event-free survival 57%. Overall and event-free survival in patients achieving pCR is 100%.PFL is active in paranasal cancer. Patients who attain a pathological complete remission have a favorable prognosis. Cardiovascular complications represent the limiting toxicity. Primary chemotherapy combined with surgery-sparing treatment approaches deserves further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|